Peter Williams, Ph.D.

Dr
Janssen Research & Development, LLC
Beerse, Antwerpen, Belgium

Disclosure: Johnson & Johnson: Employee, Shareholder

Presentation(s):

• 884 - Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies

  Thursday, October 3
  3:30 PM – 3:45 PM

• 2840 - Long Term Efficacy, Safety and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy – LATTE Week 312 Results

  Saturday, October 5
  2:15 PM – 2:30 PM